This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Neuren Pharmaceuticals Limited. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2025
Title: Etienne David Frank Philippe Moniotte: Innovator in Pharmaceutical Compositions
Introduction
Etienne David Frank Philippe Moniotte is a notable inventor based in Waterloo, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating neurodegenerative and neurodevelopmental disorders. With a total of three patents to his name, Moniotte's work is recognized for its innovative approach to drug formulation.
Latest Patents
Moniotte's latest patents focus on compositions of trofinetide. These disclosures describe compounds of Formula (I), including stereoisomers and side compounds. The patents detail pharmaceutical compositions and methods of manufacturing these compounds using silylation reagents. More specifically, they outline the manufacture of trofinetide and its side products, as well as the compositions and products containing these compounds for pharmaceutical uses.
Career Highlights
Moniotte is currently associated with Neuren Pharmaceuticals Limited, where he continues to advance his research and development efforts. His work has been pivotal in creating effective treatments for conditions that affect neurological health.
Collaborations
Moniotte has collaborated with notable colleagues such as Clive Blower and James Murray Shaw, contributing to a dynamic research environment that fosters innovation in pharmaceutical sciences.
Conclusion
Etienne David Frank Philippe Moniotte stands out as a key figure in the pharmaceutical industry, with his innovative patents paving the way for new treatments in neurodevelopmental and neurodegenerative disorders. His contributions are vital to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
